Video

Dr. Feldman on Remaining Challenges With Biomarkers in Prostate Cancer

Author(s):

Adam Scott Feldman, MD, MPH

Adam Scott Feldman, MD, MPH, urologist at Massachusetts General Hospital, assistant professor of surgery, Harvard Medical School, discusses the remaining challenges with biomarkers in prostate cancer.

Adam Scott Feldman, MD, MPH, urologist at Massachusetts General Hospital, assistant professor of surgery, Harvard Medical School, discusses the remaining challenges with biomarkers in prostate cancer.

There is a plethora of research on biomarkers, but the ones that actually affect clinical care is quite small, says Feldman.

Related Videos
Alberto Montero, MD, MBA, CPHQ, clinical director, Breast Cancer Medical Oncology Program, University Hospitals Seidman Cancer Center; associate professor, medicine, Case Western Reserve University School of Medicine
JURCZACK
Adam E. Singer, MD, PhD, health sciences clinical instructor, medicine, division lead, Kidney Cancer, Division of Hematology/Oncology, UCLA Health
Dr Burke on the Assessment of Barriers to Initiating Venetoclax-Based Regimens for CLL
Bradley McGregor, MD,
Ira Zackon, MD
Jacob E. Berchuck, MD
David A. Braun, MD, PhD
Christiane Querfeld, M.D., Ph.D
Judy Hayek, MD
Related Content
Felix Y. Feng, MD
January 22nd 2025

Felix Y. Feng, MD, Leading Radiation Oncologist and Genitourinary Cancer Researcher, Dies at 48

Oncology Unplugged
November 6th 2024

Review Key Genitourinary Cancer Data From the 2024 ESMO Congress With Chandler Park, MD

Prostate Cancer | © Sebastian Kaulitzki – stock.adobe.com
January 21st 2025

Rapid, At-Home PSA Screening Test Gains Approval in UAE for Early Detection of Prostate Cancer

Stephen Liu, MD; Sara A. Hurvitz, MD, FACP; S. Vincent Rajkumar, MD; Sumanta Kumar Pal, MD, FASCO; Shubham Pant, MD, MBBS
May 23rd 2024

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

Sotorasib doublet gets approved for KRAS G12C–mutated CRC, acalabrutinib triplet is cleared for previously untreated MCL, and more from OncLive.
January 18th 2025

The OncFive: Top Oncology Articles for the Week of 1/12

Bradley McGregor, MD
January 15th 2025

Nivolumab Plus Ipilimumab May Offer Efficacious Therapeutic Approach in Rare GU Cancers